Evidence map›Paper›PMID 40969757›Full record

ArticleFrontiers in immunology2025

Mesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series.

Su M Lwin, Shane Solanky, Cristiano Scottà, Chiara Giacomini, Shir Azrielant, Isabella Tosi, Atheer Al-Haddabi, Emelia Duarte-Williamson, Hannah Dawe, Sarah Walsh and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Su M LwinSt John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Shane SolankySt John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Cristiano ScottàCollege of Health, Medicine and Life Sciences, Department of Life Science, Biosciences, Brunel University London, London, United Kingdom.
Chiara GiacominiSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, United Kingdom.
Shir AzrielantSt John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Isabella TosiSt John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Atheer Al-HaddabiDepartment of Dermatology, King's College Hospital, London, United Kingdom.
Emelia Duarte-WilliamsonDepartment of Dermatology, King's College Hospital, London, United Kingdom.
Hannah DaweSt John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Sarah WalshDepartment of Dermatology, King's College Hospital, London, United Kingdom.
John A McGrathSt John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Giovanna LombardiPeter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom.
Francesco DazziSchool of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, United Kingdom.
Paola Di MeglioSt John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Christopher E M GriffithsSt John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine-targeted biologics have revolutionized the management of moderate-to-severe psoriasis; however, all available therapies have failed a growing number of patients. Mesenchymal stromal cells (MSCs), with their immunomodulatory properties, offer a novel therapeutic option. Here, we report the cases of three adult female patients with long-standing, severe plaque psoriasis who were refractory to multiple biologic therapies, and were consequently treated with two intravenous infusions of allogeneic umbilical cord-derived MSCs (UC-MSCs; 1.96 - 3.00 × 10

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationPsoriasisAdultBiological ProductsFemaleHumansTreatment OutcomeBiological Productsimmunomodulatorymesenchymal stromal cellsmonocytesmultiple biologic-refractorypsoriasisregulatory T cells

Identifiers

PMID40969757
PMCPMC12440939

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.